| Revenue growth | Q2 +15.1% YoY; H1 +0.6% YoY |
|---|---|
| Margins | Q2 EBITDA margin 6.2% vs -3.96% YoY; gross margin down |
| Demand visibility | API: healthy revenue visibility; overseas molecule talks ongoing |
| Management confidence | Upbeat on H2; no quantified targets |
Growth
Q2 revenue +15.1% YoY, API +71%. H1 revenue flat (+0.6%); H1 PAT inflated by ₹92.95 cr one-off share-sale gain.
Outlook
No numeric guidance. Management expects H2 optimism; pursuing overseas API molecules; RoW expansion in 0–3 yrs, EU/USA in 3–5 yrs.
Risks
Gross margin hit by inventory price adjustment and one-offs; H1 EBITDA loss ₹46.84 cr after Q1 ₹52.42 cr loss.
Investor Presentation filed with BSE, NSE: THEMISMED. Summary written with AI assistance from the document.
Themis Medicare Ltd: key numbers
- Share price
- ₹96.49
- Market cap
- ₹888.7 Cr
- Revenue (annual)
- ₹342.2 Cr
- Net profit (annual)
- ₹1.14 Cr
- P/E (TTM)
- 17.6×Sector 48.6×
- Promoter holding
- 67.11%+0.00% QoQ
- FII holding
- 0.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Themis Medicare Ltd
All →Themis Medicare Other Announcement
Themis Medicare revised its June 2026 shareholding pattern to recategorise three Vividhmargi Trust trustees as Promoter Group. Total promoter and promoter group holding is unchanged, so this is a routine disclosure.
Themis Medicare Q2 FY27 Results: Turns Profitable, Net Profit ₹7.1 Cr
Themis Medicare Ltd reported revenue from operations of ₹89.7 Cr (+15.0% YoY) and net profit of ₹7.1 Cr for Q2 FY27.
- Key figure
- Net profit ₹7.1 Cr
Themis Medicare Other Announcement
Themis Medicare has filed a revised September 2026 quarter shareholding pattern. It reclassifies trustees as promoter group and adds OSS Software Solutions as a nil-holding promoter group member.
Themis Medicare Board Meeting Date
Themis Medicare's board is scheduled for November 5, 2026, to approve quarterly and half-year financial results. The trading window remains closed until 48 hours post-results publication.
Themis Medicare Share Pledge
Promoter Vividhmargi pledged 15 lakh Themis Medicare shares for a Rs 135 Crore borrowing. Total encumbrance rises to 4.89% of capital.
- Value
- ₹135.0 Cr
Themis Medicare Management Change
Themis Medicare proposes re-appointing Independent Director Bhaskar Vemban Iyer for a second five-year term from 12 November 2026. Postal ballot notice dispatched to members seeking approval.